Incyte Corporation (INCY)
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins
Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Monjuvi/Minjuvi and Niktimvo performance. Positive phase 3 frontMIND data for Monjuvi enables a 1st-line DLBCL sBLA filing in H1 2026, expanding addressable market.
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
Incyte's blood cancer therapy meets main goal in late-stage trial
Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer.
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
Here's Why Incyte (INCY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript
Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte: This Profitable Biotech Trades Like A Melting Iceberg
Incyte's Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025 showcased 20% sales growth, 200%+ EBIT expansion, and EPS up 111%, proving operating leverage and validating management's shift of capital into higher‑return franchises. I view CALR antibody 989, povorcitinib in HS, and two de‑risking solid‑tumor agents as multiple, independent shots at post‑Jakafi multi‑billion‑dollar revenue pillars.
Incyte: Riding Jakafi, Bracing For Generic Headwinds
Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura sales, improved profitability, and disciplined R&D spending. Key risks include heavy reliance on Jakafi, with generics expected in 2028, and the pipeline's limited ability to fully offset lost revenue.
